The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

doi:10.3969/j.issn.1007-3969.2014.02.008

China Oncology ›› 2014, Vol. 24 ›› Issue (2): 128-134.doi: 10.3969/j.issn.1007-3969.2014.02.008

The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

SUN Yi-fei¹,YANG Zhong-yi¹,ZHANG Yong-ping¹,WANG Ming-wei¹,YAO Zhi-feng¹,XUE Jing¹,BAO Xiao¹,YANG Wen-tao²,SHEN Zhen-zhou³,SHAO Zhi-min³,ZHANG Ying-jian¹

1.Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
2. Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
3. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2014-02-28 Published:2014-03-07
Contact: ZHANG Ying-jian E-mail: yjzhang111@aliyun.com

Abstract

Abstract:

Background and purpose: 16α-[18F]fluoroestradiol (¹⁸F-FES) is an in vivo specific imaging agent for estrogen receptor (ER). We investigated the concordance between tumor ER status as determined by FES-PET and in vitro immunohistochemical assays. Methods: ¹⁸F-FES was prepared by ourselves. Twenty-six patients were enrolled (17 primary and 9 metastatic/recurrent). Patients underwent both ¹⁸F-FES and ¹⁸F-FDG PET/CT. Results: We found good overall agreement (96.15%) between in vitro ER assays and FES-PET. The ER status diagnosis sensitivity of ¹⁸F-FES was 93.33% and the specificity was 100% when using cut-off value of SUV_max≥1.5. There was a positive correlation between in vitro ER, PR assays and the SUV_max of ¹⁸F-FES while in vitro HER-2/neu assays correlatived negatively with ¹⁸F-FES SUV_max. Conclusion: These results suggested ¹⁸F-FES may be useful for studying the ER expression of all malignant lesions in patients with breast cancer and guiding individual therapy.

Key words: Estrogen receptor, Immunohistochemistry, ¹⁸F-FES, ¹⁸F-FDG, ER subtype

SUN Yi-fei,YANG Zhong-yi,ZHANG Yong-ping,WANG Ming-wei,YAO Zhi-feng,XUE Jing,BAO Xiao,YANG Wen-tao,SHEN Zhen-zhou,SHAO Zhi-min,ZHANG Ying-jian. The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status[J]. China Oncology, 2014, 24(2): 128-134.

[1]	XU Ran , WANG Xinyue , FENG Linyuan , HAN Anna , WANG Yixuan , YANG Wanshan , LIU Chao . Expression and biological significance of NCAPD2 in glioma [J]. China Oncology, 2021, 31(9): 789-798.
[2]	FENG Runlin , HUA Jie , KUI Xiang , LI Ruyi , YI Xiaojia , WANG Yan , TAO Yanping . A case report of metastatic pericardial myxoid liposarcoma and literature review [J]. China Oncology, 2021, 31(3): 227-230.
[3]	LIU Wei , WANG Xiaojiang , ZHANG Jing , ZHU Weifeng , PENG Fengying , WANG Jianchao , XIAO Weijin , HU Dan . Clinicopathological characteristics and prognostic analysis of medullary thyroid carcinoma in children and adolescents [J]. China Oncology, 2021, 31(11): 1096-1103.
[4]	HUANG Ling , ZOU Yourui , MA Yue , LI Zhuoqi , GAO Xinyi , ABU Lagu , MA Hui . Expression difference and clinical significance of CHKα in different grades of gliomas [J]. China Oncology, 2021, 31(10): 892-898.
[5]	WU Yanni , ZHAO Chen . Solitary fibrous tumor of thyroid: clinicopathologic analysis and literature review [J]. China Oncology, 2020, 30(6): 462-467.
[6]	WANG Lin , JIA Jing , YE Xingming , LIN Lu , CHEN Yanping , CHEN Ying . Prognostic significance of histone methyltransferase hSETD1A expression in rectal cancer [J]. China Oncology, 2020, 30(5): 369-374.
[7]	LI Yuan. Personalized immunotherapy for lung cancer under the guidance of pathology [J]. China Oncology, 2020, 30(10): 770-776.
[8]	WANG Yuhang, SONG Quanfu, WU Junqiang, Nading Abiyasi, A Leha, PANG Da, JIANG Yongdong. FGFR1 protein level is associated with ER expression and prognosis in ER-positive breast cancer [J]. China Oncology, 2019, 29(5): 345-351.
[9]	MA Jiaqiang, CAO Chunmei, Shyamal Goswami, CHEN Qin, GAO qiang, ZHANG Xiaoming. Detection of ICOS⁺T cells by multiplex immunohistochemistry in tumor tissue and its clinical significance in hepatocellular carcinoma [J]. China Oncology, 2019, 29(5): 352-361.
[10]	SUN Xiangjie, YANG Wentao. Issues on immunohistochemistry for molecular classification of breast cancer [J]. China Oncology, 2019, 29(3): 161-165.
[11]	GU Bingxin, SUN Yuyun, YANG Zhongyi, LUO Jianmin, ZHANG Jianping, ZHANG Yingjian. A dual-modality SPECT/MR probe of ^99mTc-Transferrin-DTPA-Gd for the detection of tumor transferrin receptor expression in vivo [J]. China Oncology, 2019, 29(2): 119-124.
[12]	JIN Jingjing, YIN Yulei, GU Yan, SU Minjun, XIAO Li. Feasibility study of immunohistochemistry for liquid-based cytology in pleural exfoliation examination [J]. China Oncology, 2019, 29(12): 921-926.
[13]	LI Jiawei, SHI Zhaoting, HOU Yingmin, et al. Clinicopathological and immunohistochemical basis for sonographic characteristics of triple-negative invasive breast cancer [J]. China Oncology, 2019, 29(1): 37-44.
[14]	LI Lan, YANG Daoke, LANG Jinyi, et al. Clinical analysis of a patient with primary extranodal nasal typel NK/T-cell lymphoma of the lung [J]. China Oncology, 2019, 29(1): 57-62.
[15]	ZHENG Yingying,XU Junyan,ZHANG Jianping, et al. The value of ¹⁸F-FDG PET/CT texture analysis in predicting neoadjuvant chemoradiotherapy of locally advanced rectal cancer [J]. China Oncology, 2018, 28(8): 590-594.

The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments